Cargando…

Multilevel omics for the discovery of biomarkers in pediatric sepsis

Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinyu, Li, Rubo, Qian, Suyun, Yu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693667/
https://www.ncbi.nlm.nih.gov/pubmed/38050541
http://dx.doi.org/10.1002/ped4.12405
_version_ 1785153211157446656
author Wang, Xinyu
Li, Rubo
Qian, Suyun
Yu, Dan
author_facet Wang, Xinyu
Li, Rubo
Qian, Suyun
Yu, Dan
author_sort Wang, Xinyu
collection PubMed
description Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pediatrics could be significantly different. A growing body of studies focused on finding markers in pediatric sepsis in recent years using multi‐omics approaches. This narrative review summarized the progress in studying pediatric sepsis biomarkers from genome, transcript, protein, and metabolite levels according to the omics technique that has been applied for biomarker screening. It is most likely not a single biomarker could work for precision diagnosis of sepsis, but a panel of markers and probably a combination of markers detected at multi‐levels. Importantly, we emphasize the importance of group distinction of infectious agents in sepsis patients for biomarker identification, because the host response to infection of bacteria, virus, or fungus could be substantially different and thus the results of biomarker screening. Further studies on the investigation of sepsis biomarkers that were caused by a specific group of infectious agents should be encouraged in the future, which will better improve the clinical execution of personalized medicine for pediatric sepsis.
format Online
Article
Text
id pubmed-10693667
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106936672023-12-04 Multilevel omics for the discovery of biomarkers in pediatric sepsis Wang, Xinyu Li, Rubo Qian, Suyun Yu, Dan Pediatr Investig Review Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pediatrics could be significantly different. A growing body of studies focused on finding markers in pediatric sepsis in recent years using multi‐omics approaches. This narrative review summarized the progress in studying pediatric sepsis biomarkers from genome, transcript, protein, and metabolite levels according to the omics technique that has been applied for biomarker screening. It is most likely not a single biomarker could work for precision diagnosis of sepsis, but a panel of markers and probably a combination of markers detected at multi‐levels. Importantly, we emphasize the importance of group distinction of infectious agents in sepsis patients for biomarker identification, because the host response to infection of bacteria, virus, or fungus could be substantially different and thus the results of biomarker screening. Further studies on the investigation of sepsis biomarkers that were caused by a specific group of infectious agents should be encouraged in the future, which will better improve the clinical execution of personalized medicine for pediatric sepsis. John Wiley and Sons Inc. 2023-11-21 /pmc/articles/PMC10693667/ /pubmed/38050541 http://dx.doi.org/10.1002/ped4.12405 Text en © 2023 Chinese Medical Association. Pediatric Investigation published by John Wiley & Sons Australia, Ltd on behalf of Futang Research Center of Pediatric Development. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review
Wang, Xinyu
Li, Rubo
Qian, Suyun
Yu, Dan
Multilevel omics for the discovery of biomarkers in pediatric sepsis
title Multilevel omics for the discovery of biomarkers in pediatric sepsis
title_full Multilevel omics for the discovery of biomarkers in pediatric sepsis
title_fullStr Multilevel omics for the discovery of biomarkers in pediatric sepsis
title_full_unstemmed Multilevel omics for the discovery of biomarkers in pediatric sepsis
title_short Multilevel omics for the discovery of biomarkers in pediatric sepsis
title_sort multilevel omics for the discovery of biomarkers in pediatric sepsis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693667/
https://www.ncbi.nlm.nih.gov/pubmed/38050541
http://dx.doi.org/10.1002/ped4.12405
work_keys_str_mv AT wangxinyu multilevelomicsforthediscoveryofbiomarkersinpediatricsepsis
AT lirubo multilevelomicsforthediscoveryofbiomarkersinpediatricsepsis
AT qiansuyun multilevelomicsforthediscoveryofbiomarkersinpediatricsepsis
AT yudan multilevelomicsforthediscoveryofbiomarkersinpediatricsepsis